Invitro effects of ivermectin and sulphadiazine on Toxoplasma gondii
Abstract number: P2094
Objectives: Toxoplasmosis is an infection disease caused by the obligate intracellular parasite Toxoplasma gondii occur worldwide. Currently, the most effective treatment for both congenital and acquired toxoplasmosis is the combination of pyrimethamine-sulphadiazine. The aim of this study was to investigate in vitro activities of ivermectin and sulphadiazine, against T. gondii RH strain on Hep-2 epithelial cells.
Methods: In this study, Hep-2 cells in tissue culture plates were infected with the tachyzoites isolated from peritoneal fluid of mice infected with T. gondii. Subsequently, ivermectin and sulphadiazine were added and their inhibitory activities were assessed after 24, 48 and 72 hours incubations using inverted microscopy and ELISA. The toxicities of drugs for Hep-2 cells were also determined with NRUD assay.
Results: Ivermectin was found to have significant inhibitory activity against tachyzoites after 48 h of incubation at the concentration of 5 and 2.5 microgram/ml (P < 0.01) and higher concentrations. The 50% inhibitory concentrations (IC50) of ivermectin and sulphadiazine were found 0.27 microgram/ml and 7.3 microgram/ml after 48 h of exposure, respectively. None of the concentrations tested for each drugs demonstrated toxicity to Hep-2 cells after 72 h of incubation.
Conclusion: Our results indicated that ivermectin significantly inhibited replication of the tachyzoites of T. gondii RH strain. Further studies are needed to combination of ivermectin with other drugs and animal model for toxoplasmosis treatment.
|Session name:||Abstracts 20th European Congress of Clinical Microbiology and Infectious Diseases|
|Location:||Vienna, Austria, 10 - 13 April 2010|
|Back to top|